---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099383"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:33:46.629676+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint finishes Phase 3 enrollment for DURAVYU in wet AMD; top-line data mid-2026

## Summary
- LUCIA trial enrolled and randomized over 400 patients in seven months; total >800 across both trials.
- Interim safety data consistent with prior DURAVYU trials; DSMC recommended continuation without protocol changes.
- Topline 56-week data for LUGANO expected mid-2026; LUCIA data to follow shortly after.
- DURAVYU is a sustained-release TKI for wet AMD; Phase 3 program aligned with FDA and EMA.
- DURAVYU has been evaluated in over 190 patients across four trials with favorable safety profile.

## SEC filing metadata
- accession: 0000950170-25-099383
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/0000950170-25-099383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099383
- JSON: https://secwatch.observer/filing/0000950170-25-099383.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.